Abstract Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option
In clinic trials, liraglutide 3.0mg led to an average of 8 per cent weight reduction over 56 weeks, while semaglutide 2.4mg led to an average 14.9 per cent reduction over 68 weeks
Gallbladder Issues Research shows an increase in gallbladder-related issues in GLP-1 medication users, with conditions ranging from asymptomatic gallstones to severe cholecystitis requiring surgical intervention
More broadly, Kaileras IPO arrives amid a revival of the biotech IPO market in early 2026
Our meals are designed to complement professional health guidance not replace it
If youre unsure that youve been diagnosed with the right type of diabetes, ask your doctor or endocrinologist what additional tests are available